We hypothesized that loss of CDX2 expression in tumors confers increased sensitivity to chemotherapeutic drugs, and investigated this possibility in vitro by high‐throughput drug screening and gene expression analyses of 35 CRC cell lines, where 14/35 (40%) were CDX2‐negative (Fig. 4A). The gene discussed is CDX2; the disease is colorectal carcinoma.